Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MRKR

Marker Therapeutics Inc

May 29 • 04:00PM ET

1.57

+0.06 3.97 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: ALLR BCTX CLRB JSPR LGVN NXTC PLUR PTN TPST VTGN

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.67	Insider Own	19.03%	Shs Outstand	16.67M	Perf Week	9.79%
Market Cap	26.18M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.00%	Shs Float	13.50M	Perf Month	8.28%
Enterprise Value	10.54M	PEG	-	EPS next Q	-0.22	Inst Own	12.33%	Short Float	1.81%	Perf Quarter	6.08%
Income	-10.90M	P/S	8.18	EPS this Y	-21.94%	Inst Trans	-0.59%	Short Ratio	2.24	Perf Half Y	42.73%
Sales	3.20M	P/B	1.90	EPS next Y	-5.19%	ROA	-63.30%	Short Interest	0.24M	Perf YTD	5.37%
Book/sh	0.83	P/C	1.67	EPS next 5Y	-	ROE	-77.04%	52W High	4.07 -61.43%	Perf Year	29.75%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	39.48% 33.49%	ROIC	-78.98%	52W Low	0.81 93.85%	Perf 3Y	22.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.31% 50.02%	Gross Margin	-	Volatility	5.18% 5.03%	Perf 5Y	-94.60%
Dividend TTM	-	EV/Sales	3.29	EPS Y/Y TTM	49.21%	Oper. Margin	-386.37%	ATR (14)	0.08	Perf 10Y	-97.72%
Dividend Ex-Date	-	Quick Ratio	4.79	Sales Y/Y TTM	-43.86%	Profit Margin	-340.78%	RSI (14)	61.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.79	EPS Q/Q	58.88%	SMA20	7.94%	Beta	1.43	Target Price	7.87
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	7.80%	Rel Volume	0.83	Prev Close	1.51
Employees	5	LT Debt/Eq	0.00	Earnings	May 20	SMA200	18.79%	Avg Volume	109.51K	Price	1.57
IPO	Jan 05, 1998	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% 0.00%	Trades		Volume	91,303	Change	3.97%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Initiated	Canaccord Genuity	Buy	$8
Mar-25-21	Initiated	Piper Sandler	Overweight	$6
Mar-19-21	Initiated	Cantor Fitzgerald	Overweight	$6
May-12-20	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $2.50
May-30-19	Initiated	ROTH Capital	Buy
Mar-01-19	Initiated	Janney	Buy
Dec-03-18	Upgrade	Piper Jaffray	Neutral → Overweight

Mar-18-26 05:31PM	Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results (GlobeNewswire)
Mar-05-26 05:20PM	Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-18-26 08:00AM	Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-26-26 07:00AM	Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology (GlobeNewswire) -10.95%
Jan-21-26 08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
09:36AM	Loading…
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks) -5.48%
Jan-07-26 09:55AM	MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy? (Zacks) +17.74%
08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 07:00AM	Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer (GlobeNewswire) +16.23%
Nov-14-25 07:00AM	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-05-25 07:30AM	Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors (GlobeNewswire)
Nov-03-25 09:15AM	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting (GlobeNewswire)
Oct-06-25 07:30AM	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program (GlobeNewswire) +13.10%
Aug-28-25 08:00AM	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-27-25 12:02PM	Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study (Insider Monkey) -6.01%
10:30AM	Loading…
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -20.63%
07:00AM	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma (GlobeNewswire)
Jul-30-25 08:00AM	Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-17-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.00%
Jun-17-25 08:00AM	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma (GlobeNewswire)
May-20-25 08:00AM	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma (GlobeNewswire)
May-19-25 08:00AM	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies (GlobeNewswire)
Apr-01-25 08:00AM	Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference (GlobeNewswire) -7.32%
Mar-31-25 08:45AM	Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Dec-19-24 08:06AM	Marker Therapeutics Announces $16.1 Million Private Placement (GlobeNewswire) -7.44%
08:05AM	Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma (GlobeNewswire)
Dec-17-24 07:00AM	Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer (GlobeNewswire) +17.68%
Dec-10-24 08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann and Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
11:00AM	Loading…
Nov-26-24 11:00AM	Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit (GlobeNewswire)
Nov-14-24 04:30PM	Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -12.29%
Oct-22-24 08:20AM	Marker Therapeutics price target raised to $19 from $11 at Ladenburg (TipRanks) +22.70%
Sep-26-24 02:33PM	AML cell therapy trials to watch in 2024 targeting GvHD (Clinical Trials Arena) +6.59%
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-14-24 04:30PM	Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -5.41%
Aug-12-24 07:00AM	Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma (GlobeNewswire)
Jun-28-24 11:52AM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023 (InvestorPlace) +12.42%
May-15-24 11:53PM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024 (InvestorPlace)
04:15PM	Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-08-24 07:00AM	Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies (GlobeNewswire)
Mar-25-24 05:45PM	Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results (GlobeNewswire) -10.74%
Mar-22-24 12:30PM	Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire) +5.82%
Jan-22-24 07:30AM	Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for Neldaleucel as Nonproprietary Name for MT-601 (GlobeNewswire) +5.56%
Jan-08-24 09:31AM	Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization (Benzinga)
08:24AM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization (GlobeNewswire)
Dec-21-23 11:00AM	Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-11-23 07:00AM	Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse (GlobeNewswire) +46.85%
Nov-09-23 05:00PM	Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.56%
Sep-11-23 07:00AM	Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse (GlobeNewswire) +11.41%
Aug-30-23 08:00AM	Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +6.75%
Aug-25-23 12:07PM	Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) -5.52%
Aug-17-23 09:03AM	Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies (Newsfile)
Aug-14-23 04:30PM	Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +25.75%
Aug-07-23 07:00AM	Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program (GlobeNewswire)
Jul-26-23 07:00AM	Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023 (GlobeNewswire)
Jul-22-23 08:12AM	Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95% (Simply Wall St.)
Jul-10-23 07:00AM	European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients (GlobeNewswire) +23.04%
Jun-26-23 07:00AM	Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration (GlobeNewswire) -6.59%
Jun-12-23 07:00AM	Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial (GlobeNewswire) +19.52%
May-31-23 06:30AM	Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells (GlobeNewswire) +33.84%
May-17-23 06:11AM	Marker Therapeutics First Quarter 2023 Earnings: US$0.57 loss per share (vs US$1.19 loss in 1Q 2022) (Simply Wall St.)
May-08-23 07:30AM	Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer (GlobeNewswire) +15.97%
May-01-23 07:30AM	Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady (GlobeNewswire) +16.47%
Mar-22-23 08:10AM	Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results (GlobeNewswire) -31.82%
Dec-13-22 07:23PM	Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund (American City Business Journals)
07:00AM	Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million (GlobeNewswire)
Nov-22-22 07:28AM	Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely (Simply Wall St.)
07:00AM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer (GlobeNewswire)
Nov-10-22 05:35PM	MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Marker Therapeutics Reports Q3 2022 Operating and Financial Results (GlobeNewswire)
Sep-13-22 07:00AM	Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Markers Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML (GlobeNewswire) +7.12%
Sep-08-22 07:00AM	Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire) +31.50%
Aug-11-22 04:22PM	Marker Therapeutics Reports Q2 2022 Operating and Financial Results (GlobeNewswire) -8.08% -12.24%
Aug-04-22 04:37PM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma (GlobeNewswire) +63.64%
Jun-15-22 07:06AM	Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky (Simply Wall St.)
May-13-22 07:00AM	Marker Therapeutics Reports Q1 2022 Operating and Financial Results (GlobeNewswire)
May-04-22 10:30AM	Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting (GlobeNewswire) +8.00%
Apr-26-22 07:00AM	Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf (GlobeNewswire)
Mar-17-22 05:45PM	Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results (GlobeNewswire)
Mar-07-22 04:05PM	Marker Therapeutics to Present at Two Upcoming March Investor Conferences (GlobeNewswire) +8.86%
Feb-17-22 01:08PM	Why Are Marker Therapeutics Shares Trading Lower On Thursday? (Benzinga) -25.99%
Feb-16-22 04:30PM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion (GlobeNewswire)
Feb-08-22 04:05PM	Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022 (GlobeNewswire)
Jan-20-22 06:38AM	Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer (Benzinga) -10.67%
Jan-19-22 04:49PM	Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer (GlobeNewswire)
Jan-06-22 08:53AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.) -5.51%
Dec-31-21 09:40AM	Are Options Traders Betting on a Big Move in Marker Therapeutics (MRKR) Stock? (Zacks)
Dec-09-21 07:00AM	Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors (PR Newswire)
Nov-18-21 04:05PM	Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting (PR Newswire) -7.35%
Nov-10-21 04:05PM	Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results (PR Newswire)
Oct-08-21 09:24AM	Bullish insiders bet US$1.3m on Marker Therapeutics, Inc. (NASDAQ:MRKR) (Simply Wall St.)
Sep-07-21 04:05PM	Marker Therapeutics to Present at Three Upcoming September Investor Conferences (PR Newswire)
Aug-20-21 12:00PM	38 Stocks Moving In Friday's Mid-Day Session (Benzinga) +8.33%
Aug-19-21 04:05PM	Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas (PR Newswire) -5.08%
Aug-10-21 04:01PM	Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results (PR Newswire)
Aug-09-21 06:57AM	Is Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-28-21 04:05PM	Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility (PR Newswire)
Jul-06-21 07:00AM	Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML (PR Newswire)
Jun-29-21 09:01AM	Marker Therapeutics, Inc. (MRKR): Are Hedge Funds Right About This Stock? (Insider Monkey)

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Co-FounderDr. Juan F. Vera M.D.

Director of AdministrationMs. Elizabeth Donnelly

Director of Corporate Operations & External CommunicationsDr. Maria-Bernadette Madel Ph.D.

Vice President of Human ResourcesMr. Edmund Cheung

Head of Clinical OperationsPatricia Allison

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRKR

Marker Therapeutics Inc

Upgrade your Finviz experience